Abstract
Inhibition of prostaglandin biosynthesis via inhibition of the fatty acid cyclooxygenase (COX) is the mechanism of action of non-steroidal antiinflammatory drugs (NSAIDs). This results in an inhibition of the inflammatory and pain-producing activities of prostaglandins at a site of tissue injury but also in inhibition of prostaglandin production in the gastrointestinal tract (GI) and platelets, i.e. sites where endogenous prostaglandins are possibly involved in control of physiological functions. The discovery of two COX isoenzymes, COX-1 and COX-2, and the detection of their separate function and regulation, has initiated the search for new and putatively more selective inhibitors of prostaglandin biosynthesis. Specifically, selective inhibitors of COX-2 were developed in order to improve the anti-inflammatory and analgetic specificity and potency of the compounds and to reduce side-effects in the GI tract. Available experimental and clinical data of selective COX-2 inhibitors, including flosulide, celecoxib or rofecoxib, suggest improved gastric tolerance as compared to conventional, non-selective NSAIDs. However, experimental evidence suggests that both, the analgetic and anti-inflammatory action of COXinhibitors, might also require inhibition of COX-1. COX-2-selective compounds at antiinflammatory doses might have other side-effects, and for example reduce vascular prostacyclin production. Evidence is accumulating that COX-2 might not only be considered as a putatively detrimental enzyme but rather a highly regulated enzyme that also contributes to tissue protection and is even constitutively expressed in healthy human stomach mucosa. This paper reviews some of these newer aspects of COX-2-selective inhibitors in clinical use and discusses their possible benefits and risks.
Current Medicinal Chemistry
Title: Cyclooxygenase-2 Inhibition and Side-effects of Non-steroidal Antiinflammatory Drugs in the Gastrointestinal Tract.
Volume: 7 Issue: 11
Author(s): J. Meyer-Kirchrath and K. Schror
Affiliation:
Abstract: Inhibition of prostaglandin biosynthesis via inhibition of the fatty acid cyclooxygenase (COX) is the mechanism of action of non-steroidal antiinflammatory drugs (NSAIDs). This results in an inhibition of the inflammatory and pain-producing activities of prostaglandins at a site of tissue injury but also in inhibition of prostaglandin production in the gastrointestinal tract (GI) and platelets, i.e. sites where endogenous prostaglandins are possibly involved in control of physiological functions. The discovery of two COX isoenzymes, COX-1 and COX-2, and the detection of their separate function and regulation, has initiated the search for new and putatively more selective inhibitors of prostaglandin biosynthesis. Specifically, selective inhibitors of COX-2 were developed in order to improve the anti-inflammatory and analgetic specificity and potency of the compounds and to reduce side-effects in the GI tract. Available experimental and clinical data of selective COX-2 inhibitors, including flosulide, celecoxib or rofecoxib, suggest improved gastric tolerance as compared to conventional, non-selective NSAIDs. However, experimental evidence suggests that both, the analgetic and anti-inflammatory action of COXinhibitors, might also require inhibition of COX-1. COX-2-selective compounds at antiinflammatory doses might have other side-effects, and for example reduce vascular prostacyclin production. Evidence is accumulating that COX-2 might not only be considered as a putatively detrimental enzyme but rather a highly regulated enzyme that also contributes to tissue protection and is even constitutively expressed in healthy human stomach mucosa. This paper reviews some of these newer aspects of COX-2-selective inhibitors in clinical use and discusses their possible benefits and risks.
Export Options
About this article
Cite this article as:
Meyer-Kirchrath J. and Schror K., Cyclooxygenase-2 Inhibition and Side-effects of Non-steroidal Antiinflammatory Drugs in the Gastrointestinal Tract., Current Medicinal Chemistry 2000; 7 (11) . https://dx.doi.org/10.2174/0929867003374219
DOI https://dx.doi.org/10.2174/0929867003374219 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
CTLA-4Ig: Uses and Future Directions
Recent Patents on Inflammation & Allergy Drug Discovery Editorial [Hot Topic: COX-2 Inhibition in Gastroenterology and Rheumatolgy:Current Challenges and Perspectives for the Future (Executive Editor: Angel Lanas)]
Current Pharmaceutical Design Epidemiology of Ischemic Heart Disease and Diabetes in South Asia: An Overview of the Twin Epidemic
Current Diabetes Reviews Anti Tumor Necrosis Factor Alpha (TNFα) Therapy in Ankylosing Spondylitis - Asian Perspective
Current Rheumatology Reviews Aspirin: from a Historical Perspective
Recent Patents on Cardiovascular Drug Discovery Novel Therapeutic Approaches in Rheumatoid Arthritis: Role of Janus Kinases Inhibitors
Current Medicinal Chemistry Chemical Constituents and Biological Activities of Cordia myxa L.: A Review
The Natural Products Journal Plant Natural Products as a Potential Source for Antibacterial Agents: Recent Trends
Anti-Infective Agents in Medicinal Chemistry Potential of Selected Indian Herbs for COVID-19
Current Traditional Medicine Heart Failure in East Asia
Current Cardiology Reviews Identification of Novel Anti-inflammatory Agents from Ayurvedic Medicine for Prevention of Chronic Diseases: “Reverse Pharmacology” and “Bedside to Bench” Approach
Current Drug Targets Antiplatelet Therapy in Children: Why So Different from Adults’?
Current Pharmaceutical Design Connective Tissue Remodeling: Cross-Talk between Endothelins and Matrix Metalloproteinases
Current Vascular Pharmacology Therapeutic Options for the Management of Aromatase Inhibitor- Associated Bone Loss
Endocrine, Metabolic & Immune Disorders - Drug Targets Inflammation in Coronary Artery Disease and Acute Myocardial Infarction - is the Stage Set for Novel Therapies?
Current Pharmaceutical Design Lipid Peroxidation End-Products as Modulators of Catabolic and Inflammatory Responses in Arthritis: A Review
Current Rheumatology Reviews Societal and Cultural Attitudes to Gout: An Important Consideration in the Successful Management of Gout among Maori in Aotearoa New Zealand
Current Rheumatology Reviews Endothelial (Dys)Function in Lone Atrial Fibrillation
Current Pharmaceutical Design Patent Selections
Recent Patents on Biotechnology Challenge of Mesenchymal Stem Cells Against Diabetic Foot Ulcer
Current Stem Cell Research & Therapy